Australia's Bioxyne hits 2-week low on drop in HY23 sales revenue

BLS Pharmaceuticals

27/01/2023 04:06

** Shares of Australia's Bioxyne  BXN.AX  fall as much as 4%
to A$0.024
    ** Stock hits lowest and eyes worst day since Jan.11, if
losses hold  
    ** Health and wellness products co posts sales revenue for
HY23 of A$1.20 mln  ($853,320.00) vs A$1.36 mln in previous year
    ** Stock has risen 4.2% this year, as of last close after
shedding 17% in 2022 
    ($1 = 1.4063 Australian dollars)
 (Reporting by Nausheen Thusoo in Bengaluru)
 ((Nausheen.Thusoo@thomsonreuters.com;))